VBI Vaccines’ Revenue Soars, Promising Vaccine Trials

VBI Vaccines Inc (VBIV) has released an update.

VBI Vaccines Inc. has reported a significant 105% increase in global net revenue for its Hepatitis B vaccine, PreHevbrio, in Q1 2024 compared to the same period last year. The company has also shared promising early data from a Phase 2b study of its cancer vaccine candidate, VBI-1901, in treating recurrent glioblastoma, with more results anticipated later in the year. Additionally, VBI is exploring strategic partnerships to advance its novel mRNA-based vaccine technology platform.

For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.